Koyfin Home > Directory > Health Care > Aclaris Therapts

Aclaris Therapts Price Chart ACRS

Historical daily share price chart and data for Aclaris Therapts since 2015 adjusted for splits and dividends. The latest closing price for Aclaris Therapts as of September 18, 2020 is $2.53.
  • In 2020 the stock opened at $1.92 and closed at $2.53 for a gain of 24% YTD.
  • In 2019 the stock opened at $7.26 and closed at $1.89 for a loss of -284%.
  • In 2018 the stock opened at $24.88 and closed at $7.39 for a loss of -237%.
  • In 2017 the stock opened at $27.21 and closed at $24.66 for a loss of -10%.
View Chart On Koyfin

Aclaris Therapts Summary

Stock Symbol: ACRS

Aclaris Therapts Company Info

Aclaris Therapeutics, Inc., a biopharmaceutical company, focuses on developing drug candidates for immuno-inflammatory diseases in the United States. It operates in two segments, Therapeutics and Contract Research. The company offers ESKATA, a formulation of high-concentration hydrogen peroxide topical solution for raised seborrheic keratosis, a common non-malignant skin tumor. It is also developing A-101, a high-concentration formulation of hydrogen peroxide that is in Phase III clinical trial for common warts; and ATI-501 and ATI-502 Janus kinase (JAK) inhibitors, which are in Phase II clinical trials for alopecia areata (AA) and other dermatological indications. In addition, the company’s products under development include ATI-450 an investigational oral, novel, small molecule selective MK2 inhibitor compound for the treatment of rheumatoid arthritis; ATI-1777 soft inhibitor for atopic dermatitis; and ATI-2138, an investigational oral ITK/TXK/JAK3, or ITJ, inhibitor compound, for the treatment of psoriasis inflammatory bowel disease. Further, it provides contract research services. Aclaris Therapeutics, Inc. has a license and collaboration agreement with Rigel Pharmaceuticals, Inc. for the development and commercialization of JAK inhibitors. The company was founded in 2012 and is headquartered in Wayne, Pennsylvania.
Market Cap
Dividend Yield
0 %
Beta vs SPX
Short Interest
67.17 %
30D Volatility
Hedge Fund Held
40.82 %

Last 10 Days of ACRS Prices